 |
 |
醫(yī)學(xué)論文范文:復(fù)方貞術(shù)調(diào)脂膠囊對(duì)大鼠非酒精性脂肪肝的影響
【摘要】目的 探討復(fù)方貞術(shù)調(diào)脂膠囊對(duì)大鼠非酒精性脂肪肝的影響,為其臨床用藥提供依據(jù)。方法 取SD大鼠60只,隨機(jī)分成正常組、模型組、復(fù)方貞術(shù)調(diào)脂膠囊高、中、低組、非諾貝特組。除正常組外,其他組采用高脂乳劑灌胃復(fù)制大鼠非酒精性脂肪肝模型,造模同時(shí)復(fù)方貞術(shù)調(diào)脂膠囊高、中、低組、非諾貝特組連續(xù)給藥8周后,測(cè)定肝臟膽固醇（TC)、三酰甘油（TG),并計(jì)算肝指數(shù),光鏡下觀察肝臟病理學(xué)變化。結(jié)果 復(fù)方貞術(shù)調(diào)脂膠囊能降低肝臟TC和肝指數(shù)。肝臟病理切片結(jié)果顯示復(fù)方貞術(shù)調(diào)脂膠囊組肝細(xì)胞脂肪變性、水樣變性及壞死和炎癥細(xì)胞浸潤(rùn)等病理表現(xiàn)均有所減輕,明顯輕于模型組。結(jié)論 復(fù)方貞術(shù)調(diào)脂膠囊對(duì)非酒精性脂肪肝有較好的防治作用。
【關(guān)鍵詞】 復(fù)方貞術(shù)調(diào)脂膠囊 非酒精性脂肪肝 病理 肝指數(shù)
The influence of compound Zhenzhu Tiaozhi capsules on nonalcoholic fatty liver disease (NAFLD) in rats
CHEN Fangchao,GUO Jiao,YANG Chaoyan, GONG Mengjuan,LU Xiaoping,TANG Chunping
(Section of Pharmacology of Chinese Medicine,Guangdong Pharmaceutical College, Guangzhou,Guangdong 510006,China)
Abstract:Objective To study the effects of compound Zhenzhu Tiaozhi capsules on nonalcoholic fatty liver disease (NAFLD) in rats. Methods 60 SD Rats were randomly divided into 6 groups: normal group, model group, compound Zhenzhu Tiaozhi capsules high dose group, moderate dose group, low dose group, and the fenofibrate group. Rats model with nonalcoholic fatty liver disease were established with administration of high fat emulsion by gavage. The rats in the treatment groups were administered with test drugs．After 8 weeks，liver cholesterol (TC), triglyeride (TG) were determined and liver index was calculated. Pathological changes in liver were observed by light microscopy. Results The liver TC and liver index of the rats administered with compound Zhenzhu Tiaozhi capsules were significantly reduced, and pathological changes were significantly ameliorated in the rats administered wit compound Zhenzhu Tiaozhi capsules. Conclusions Compound Zhenzhu Tiaozhi capsules has better therapeutic effects on nonalcoholic fatty liver disease in rats醫(yī).學(xué)全.在.線網(wǎng)站m.zxtf.net.cn．
Key words:compound Zhenzhu Tiaozhi capsule; nonalcoholic fatty liver; pathology; liver index
近年來(lái),隨著人們飲食結(jié)構(gòu)、生活方式的改變,肥胖癥、糖尿病、高脂血癥患者日益增多,導(dǎo)致非酒精性脂肪肝（nonalcoholic fatty liver，NAFL)的發(fā)病率也逐年增加,已成為現(xiàn)今社會(huì)的多發(fā)病、常見(jiàn)病［1］。研究表明：NAFL在較短期內(nèi)可發(fā)展為不可逆的肝損害,其肝纖維化的發(fā)生率高達(dá)25％［2］。因此積極發(fā)現(xiàn)和防治脂肪肝對(duì)阻止慢性肝病進(jìn)展有著十分重要的意義。
脂肪肝多伴有高脂血癥,大部分需要降血脂治療［3］。復(fù)方貞術(shù)調(diào)脂膠囊為我院郭姣教授經(jīng)驗(yàn)方, 臨床具有較好的降血脂療效。該組方已獲得國(guó)家發(fā)明專(zhuān)利授權(quán)(ZL2004100512504),前期實(shí)驗(yàn)中已證實(shí)復(fù)方貞術(shù)調(diào)脂膠囊具有調(diào)節(jié)血脂代謝異常作用,對(duì)高脂血癥有防治作用［4］。在此基礎(chǔ)上，本實(shí)驗(yàn)旨在進(jìn)一步探討復(fù)方貞術(shù)調(diào)脂膠囊對(duì)高脂飲食誘導(dǎo)的NAFL大鼠肝臟脂質(zhì)和肝臟病理學(xué)形態(tài)變化的影響,為臨床治療非酒精性脂肪肝提供科學(xué)依據(jù)。
